论文部分内容阅读
宇部兴产公司于2013年2月8日宣布,将在2014年3月停止在日本大阪府堺市生产联合装置的己内酰胺生产。这一决定是因为从2012年起,随着全球经济增长放缓,对己内酰胺的需求增长减弱,而中国己内酰胺的市场份额又大为扩大。与此同时,原料苯和辅助材料的价格也有所上涨,导致己内酰胺业务的盈利能力迅速下降。宇部兴产也将停止在堺市工厂生产的相关衍生产品。2014年3月,在堺市
Ube Industries announced on February 8, 2013 that it will cease caprolactam production at its joint plant in Sakai City, Osaka Prefecture, Japan in March 2014. This decision is due to the sluggish global growth slowing the growth of demand for caprolactam since 2012, while the market share of China’s caprolactam has greatly expanded. At the same time, the prices of raw materials benzene and auxiliary materials also increased, resulting in the rapid decline of the profitability of the caprolactam business. Ube Industries will also discontinue the production of related derivatives at Sakai City. March 2014 in Sakai City